Clinical utility of neuroprotective agents in neurodegenerative diseases: Current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis

Petra Dunkel, Christina Ll Chai, B. Sperlágh, Paul B. Huleatt, P. Mátyus

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Introduction: According to the definition of the Committee to Identify Neuroprotective Agents in Parkinson's Disease (CINAPS), "neuroprotection would be any intervention that favourably influences the disease process or underlying pathogenesis to produce enduring benefits for patients" [Meissner W, et al. Trends Pharmacol Sci 2004;25:249-253]. Preferably, neuroprotective agents should be used before or eventually during the prodromal phase of the diseases that could start decades before the appearance of symptoms. Although several symptomatic drugs are available, a disease-modifying agent is still elusive. Areas covered: The aim of the present review is to give an overview of neuroprotective agents being currently investigated for the treatment of AD, PD, HD and ALS in clinical phases. Expert opinion: Development of effective neuroprotective therapies resulting in clinically meaningful results is hampered by several factors in all research stages, both conceptual and methodological. Novel solutions might be offered by evaluation of new targets throughout clinical studies, therapies emerging from drug repositioning approaches, multi-target approaches and network pharmacology.

Original languageEnglish
Pages (from-to)1267-1308
Number of pages42
JournalExpert Opinion on Investigational Drugs
Volume21
Issue number9
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Huntington Disease
Amyotrophic Lateral Sclerosis
Neuroprotective Agents
Neurodegenerative Diseases
Parkinson Disease
Alzheimer Disease
Drug Repositioning
Pharmaceutical Preparations
Expert Testimony
Therapeutics
Pharmacology
Research

Keywords

  • Alzheimer's disease
  • Amyotrophic lateral sclerosis
  • Huntington's disease
  • Multi-target-directed ligands
  • Neurodegenerative
  • Neuroprotective
  • Parkinson's disease

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{b25386ea18104827bcdd22033883b27b,
title = "Clinical utility of neuroprotective agents in neurodegenerative diseases: Current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis",
abstract = "Introduction: According to the definition of the Committee to Identify Neuroprotective Agents in Parkinson's Disease (CINAPS), {"}neuroprotection would be any intervention that favourably influences the disease process or underlying pathogenesis to produce enduring benefits for patients{"} [Meissner W, et al. Trends Pharmacol Sci 2004;25:249-253]. Preferably, neuroprotective agents should be used before or eventually during the prodromal phase of the diseases that could start decades before the appearance of symptoms. Although several symptomatic drugs are available, a disease-modifying agent is still elusive. Areas covered: The aim of the present review is to give an overview of neuroprotective agents being currently investigated for the treatment of AD, PD, HD and ALS in clinical phases. Expert opinion: Development of effective neuroprotective therapies resulting in clinically meaningful results is hampered by several factors in all research stages, both conceptual and methodological. Novel solutions might be offered by evaluation of new targets throughout clinical studies, therapies emerging from drug repositioning approaches, multi-target approaches and network pharmacology.",
keywords = "Alzheimer's disease, Amyotrophic lateral sclerosis, Huntington's disease, Multi-target-directed ligands, Neurodegenerative, Neuroprotective, Parkinson's disease",
author = "Petra Dunkel and Chai, {Christina Ll} and B. Sperl{\'a}gh and Huleatt, {Paul B.} and P. M{\'a}tyus",
year = "2012",
month = "9",
doi = "10.1517/13543784.2012.703178",
language = "English",
volume = "21",
pages = "1267--1308",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "9",

}

TY - JOUR

T1 - Clinical utility of neuroprotective agents in neurodegenerative diseases

T2 - Current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis

AU - Dunkel, Petra

AU - Chai, Christina Ll

AU - Sperlágh, B.

AU - Huleatt, Paul B.

AU - Mátyus, P.

PY - 2012/9

Y1 - 2012/9

N2 - Introduction: According to the definition of the Committee to Identify Neuroprotective Agents in Parkinson's Disease (CINAPS), "neuroprotection would be any intervention that favourably influences the disease process or underlying pathogenesis to produce enduring benefits for patients" [Meissner W, et al. Trends Pharmacol Sci 2004;25:249-253]. Preferably, neuroprotective agents should be used before or eventually during the prodromal phase of the diseases that could start decades before the appearance of symptoms. Although several symptomatic drugs are available, a disease-modifying agent is still elusive. Areas covered: The aim of the present review is to give an overview of neuroprotective agents being currently investigated for the treatment of AD, PD, HD and ALS in clinical phases. Expert opinion: Development of effective neuroprotective therapies resulting in clinically meaningful results is hampered by several factors in all research stages, both conceptual and methodological. Novel solutions might be offered by evaluation of new targets throughout clinical studies, therapies emerging from drug repositioning approaches, multi-target approaches and network pharmacology.

AB - Introduction: According to the definition of the Committee to Identify Neuroprotective Agents in Parkinson's Disease (CINAPS), "neuroprotection would be any intervention that favourably influences the disease process or underlying pathogenesis to produce enduring benefits for patients" [Meissner W, et al. Trends Pharmacol Sci 2004;25:249-253]. Preferably, neuroprotective agents should be used before or eventually during the prodromal phase of the diseases that could start decades before the appearance of symptoms. Although several symptomatic drugs are available, a disease-modifying agent is still elusive. Areas covered: The aim of the present review is to give an overview of neuroprotective agents being currently investigated for the treatment of AD, PD, HD and ALS in clinical phases. Expert opinion: Development of effective neuroprotective therapies resulting in clinically meaningful results is hampered by several factors in all research stages, both conceptual and methodological. Novel solutions might be offered by evaluation of new targets throughout clinical studies, therapies emerging from drug repositioning approaches, multi-target approaches and network pharmacology.

KW - Alzheimer's disease

KW - Amyotrophic lateral sclerosis

KW - Huntington's disease

KW - Multi-target-directed ligands

KW - Neurodegenerative

KW - Neuroprotective

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84865309350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865309350&partnerID=8YFLogxK

U2 - 10.1517/13543784.2012.703178

DO - 10.1517/13543784.2012.703178

M3 - Article

C2 - 22741814

AN - SCOPUS:84865309350

VL - 21

SP - 1267

EP - 1308

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 9

ER -